Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616185 | 0.84 | CDK4 (0.51) | CCND3CDK6CCNA2CDK2CDK9 | |
| SCHEMBL27315749 | 0.78 | WNT3A (0.55) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL4875684 | 0.77 | CDK4 (0.56) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL11977223 | 0.76 | CCND3 (0.53) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL4245296 | 0.76 | SYK (0.55) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL14681895 | 0.75 | CDK4 (0.55) | CCND3CDK6CCNA2CDK2CDK9 | |
| SCHEMBL4065950 | 0.74 | SYK (0.53) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL4065296 | 0.74 | CDK4 (0.51) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL18608291 | 0.74 | CDK4 (0.48) | CCND3CDK6CCNKCCNA2CDK2 | |
| SCHEMBL7712932 | 0.74 | MARK3 (0.53) | CCND3CDK6CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CCND3 782/4885CDK6 28/4885CCNK 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.